Beneficial Effects of Oral Carbon Monoxide on Doxorubicin‐Induced Cardiotoxicity

• Published in: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
• Main Authors: Rodrigo W. Alves de Souza, Vanessa Voltarelli, David Gallo, Sidharth Shankar, Michael S. Tift, Mark Young, Edward Gomperts, Andrew Gomperts, Leo E. Otterbein
• Format: Article
• Language: English
• Published: Wiley 2024-05-01
• Subjects: anthracyclines; cancer; carbon monoxide; cardiotoxicity; heme oxygenase‐1
• Online Access: https://www.ahajournals.org/doi/10.1161/JAHA.123.032067

Background Doxorubicin and other anthracyclines are crucial cancer treatment drugs. However, they are associated with significant cardiotoxicity, severely affecting patient care and limiting dosage and usage. Previous studies have shown that low carbon monoxide (CO) concentrations protect against doxorubicin toxicity. However, traditional methods of CO delivery pose complex challenges for daily administration, such as dosing and toxicity. To address these challenges, we developed a novel oral liquid drug product containing CO (HBI‐002) that can be easily self‐administered by patients with cancer undergoing doxorubicin treatment, resulting in CO being delivered through the upper gastrointestinal tract. Methods and Results HBI‐002 was tested in a murine model of doxorubicin cardiotoxicity in the presence and absence of lung or breast cancer. The mice received HBI‐002 twice daily before doxorubicin administration and experienced increased carboxyhemoglobin levels from a baseline of ≈1% to 7%. Heart tissue from mice treated with HBI‐002 had a 6.3‐fold increase in CO concentrations and higher expression of the cytoprotective enzyme heme oxygenase‐1 compared with placebo control. In both acute and chronic doxorubicin toxicity scenarios, HBI‐002 protected the heart from cardiotoxic effects, including limiting tissue damage and cardiac dysfunction and improving survival. In addition, HBI‐002 did not compromise the efficacy of doxorubicin in reducing tumor volume, but rather enhanced the sensitivity of breast 4T1 cancer cells to doxorubicin while simultaneously protecting cardiac function. Conclusions These findings strongly support using HBI‐002 as a cardioprotective agent that maintains the therapeutic benefits of doxorubicin cancer treatment while mitigating cardiac damage.